Berenberg Updates Haleon Estimates After H1 Report; Buy Rating Kept

07:02 AM EDT, 08/05/2026 (MT Newswires) -- Berenberg revised its estimates for Haleon (HLN.L) as analysts took note of the company's first-half performance in a Wednesday research report. For the six months ended June 30, the British consumer healthcare company reported revenue of 5.60 billion pounds sterling, up 2.2% year over year, while gross profit rose 4.7% to 3.69 billion pounds. "While performance was impeded by a weak cold and flu season and softer European consumption, we note investments in North America, China and Latin America are starting to bear fruit. We believe improved agility and execution are reflected in the step up in market share gained/maintained in H126 to 73% (60% in FY25)," analysts said. Against this backdrop, the research firm lifted its EBIT and EPS estimates for 2026 through 2028. On the flip side, sales forecasts were trimmed across the three-year period, with analysts also noting the company's latest management commentary and foreign exchange rates. The stock's buy rating was kept, while its price target was increased to 5.14 pounds sterling from 5.12 pounds.